CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future Perspectives

Introduction: Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment, showing significant success in hematologic malignancies. However, its application in solid tumors like gastrointestinal (GI) and head and neck cancers, as well as autoimmune diseases, remains a challen...

Full description

Saved in:
Bibliographic Details
Main Authors: Martyna Kania, Hanna Bartkowiak, Damian Grubski, Agnieszka Adamowska, Filip Nadolny, Julia Janecka, Jędrzej Jabłoński, Alicja Śniatała, Michał Hofman, Adam Dudek
Format: Article
Language:English
Published: Kazimierz Wielki University 2025-05-01
Series:Journal of Education, Health and Sport
Subjects:
Online Access:https://apcz.umk.pl/JEHS/article/view/59839
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850190639381086208
author Martyna Kania
Hanna Bartkowiak
Damian Grubski
Agnieszka Adamowska
Filip Nadolny
Julia Janecka
Jędrzej Jabłoński
Alicja Śniatała
Michał Hofman
Adam Dudek
author_facet Martyna Kania
Hanna Bartkowiak
Damian Grubski
Agnieszka Adamowska
Filip Nadolny
Julia Janecka
Jędrzej Jabłoński
Alicja Śniatała
Michał Hofman
Adam Dudek
author_sort Martyna Kania
collection DOAJ
description Introduction: Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment, showing significant success in hematologic malignancies. However, its application in solid tumors like gastrointestinal (GI) and head and neck cancers, as well as autoimmune diseases, remains a challenge. The development of CAR-T cell therapy for these indications presents unique difficulties, including tumor heterogeneity, antigen specificity, and immune suppression within the tumor microenvironment. Aim of the study: This review aims to provide an in-depth analysis of the current advancements in CAR-T cell therapy for gastrointestinal cancer, head and neck cancer, and autoimmune diseases. We seek to evaluate the therapeutic potential, current challenges, and future directions of CAR-T cell-based interventions in these conditions. Materials and methods: We performed a comprehensive literature review, analyzing recent clinical trials, preclinical studies, and research published in PubMed and Google Scholar. We focused on CAR-T cell therapy targeting solid tumors and autoimmune diseases, current treatment options, clinical efficacy, and safety concerns across these therapeutic areas.  Conclusions: CAR-T cell therapy has shown promising potential in the treatment of gastrointestinal cancers, head and neck cancers, and autoimmune diseases, but its clinical application remains limited by challenges such as antigen escape, off-tumor toxicity, and insufficient T-cell persistence. Future studies must focus on improving CAR design, enhancing targeting accuracy, and addressing the immunosuppressive tumor environment to unlock the full therapeutic potential of CAR-T cells for these indications.
format Article
id doaj-art-1d3e1b6c50b44e9595936314a26f6aa5
institution OA Journals
issn 2391-8306
language English
publishDate 2025-05-01
publisher Kazimierz Wielki University
record_format Article
series Journal of Education, Health and Sport
spelling doaj-art-1d3e1b6c50b44e9595936314a26f6aa52025-08-20T02:15:12ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062025-05-018110.12775/JEHS.2025.81.59839CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future PerspectivesMartyna Kania0https://orcid.org/0009-0006-4400-0258Hanna Bartkowiak 1https://orcid.org/0009-0000-6914-4908Damian Grubski2https://orcid.org/0009-0003-9501-9950Agnieszka Adamowska3https://orcid.org/0009-0009-1977-2522Filip Nadolny4https://orcid.org/0009-0000-6433-5975Julia Janecka5https://orcid.org/0009-0005-9011-817XJędrzej Jabłoński6https://orcid.org/0009-0009-6204-407XAlicja Śniatała7https://orcid.org/0009-0003-8488-3268Michał Hofman8https://orcid.org/0000-0001-9365-4537Adam Dudek9https://orcid.org/0009-0001-3373-2625University Hospital in PoznanJózef Struś Multispecialist Muncipal Hospital Szwajcarska 3, 61-285 Poznań Józef Struś Multispecialist Municipal Hospital Szwajcarska 3, 61-285 PoznańJózef Struś Multispecialist Muncipal Hospital; Szwajcarska 3, 61-285 PoznańUniversity Hospital in Poznań Przybyszewskiego 49, 60-355 Poznań University Hospital in Poznań Przybyszewskiego 49, 60-355 Poznań Regional Hospital in Poznań, Juraszów 7-19, 60-479 PoznańRegional Hospital in Poznań, Juraszów 7-19, 60-479 PoznańMedical Center HCP 28 czerwca 1956 r. nr 194, 61-485 PoznańUniversity Hospital in Poznań Przybyszewskiego 49, 60-355 Poznań Introduction: Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment, showing significant success in hematologic malignancies. However, its application in solid tumors like gastrointestinal (GI) and head and neck cancers, as well as autoimmune diseases, remains a challenge. The development of CAR-T cell therapy for these indications presents unique difficulties, including tumor heterogeneity, antigen specificity, and immune suppression within the tumor microenvironment. Aim of the study: This review aims to provide an in-depth analysis of the current advancements in CAR-T cell therapy for gastrointestinal cancer, head and neck cancer, and autoimmune diseases. We seek to evaluate the therapeutic potential, current challenges, and future directions of CAR-T cell-based interventions in these conditions. Materials and methods: We performed a comprehensive literature review, analyzing recent clinical trials, preclinical studies, and research published in PubMed and Google Scholar. We focused on CAR-T cell therapy targeting solid tumors and autoimmune diseases, current treatment options, clinical efficacy, and safety concerns across these therapeutic areas.  Conclusions: CAR-T cell therapy has shown promising potential in the treatment of gastrointestinal cancers, head and neck cancers, and autoimmune diseases, but its clinical application remains limited by challenges such as antigen escape, off-tumor toxicity, and insufficient T-cell persistence. Future studies must focus on improving CAR design, enhancing targeting accuracy, and addressing the immunosuppressive tumor environment to unlock the full therapeutic potential of CAR-T cells for these indications. https://apcz.umk.pl/JEHS/article/view/59839CAR-TChimeric Antigen ReceptorHead and Neck CancerSystemic Lupus ErythematosusImmunotherapyGastrointestinal tumors
spellingShingle Martyna Kania
Hanna Bartkowiak
Damian Grubski
Agnieszka Adamowska
Filip Nadolny
Julia Janecka
Jędrzej Jabłoński
Alicja Śniatała
Michał Hofman
Adam Dudek
CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future Perspectives
Journal of Education, Health and Sport
CAR-T
Chimeric Antigen Receptor
Head and Neck Cancer
Systemic Lupus Erythematosus
Immunotherapy
Gastrointestinal tumors
title CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future Perspectives
title_full CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future Perspectives
title_fullStr CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future Perspectives
title_full_unstemmed CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future Perspectives
title_short CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future Perspectives
title_sort car t cell therapy in gastrointestinal cancer head and neck cancer and autoimmune diseases current advances and future perspectives
topic CAR-T
Chimeric Antigen Receptor
Head and Neck Cancer
Systemic Lupus Erythematosus
Immunotherapy
Gastrointestinal tumors
url https://apcz.umk.pl/JEHS/article/view/59839
work_keys_str_mv AT martynakania cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT hannabartkowiak cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT damiangrubski cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT agnieszkaadamowska cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT filipnadolny cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT juliajanecka cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT jedrzejjabłonski cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT alicjasniatała cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT michałhofman cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives
AT adamdudek cartcelltherapyingastrointestinalcancerheadandneckcancerandautoimmunediseasescurrentadvancesandfutureperspectives